Related Experiment Video
Updated: Jun 6, 2025

Author Spotlight: Decoding Mitochondrial Aging
Published on: June 30, 2023
Exacerbated mitochondrial dynamic abnormalities without evident tau pathology in rapidly progressive Alzheimer's
Yanbin Xiyang1,2, Ju Gao1, Mao Ding1
1Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
Background:
Rapidly progressive Alzheimer's disease (rpAD) is a clinical subtype distinguished by its rapid cognitive decline and shorter disease duration. rpAD, like typical AD (tAD), is characterized by underlying neuropathology of amyloid plaques and neurofibrillary tangles. There is early evidence that the composition of amyloid plaques could vary between the rpAD and tAD. Differences in tau pathology between rpAD and tAD are also of interest. Additionally, mitochondrial dysfunction is a key early-stage change in tAD but has not yet been evaluated in rpAD.
Objective:
To deepen our understanding of the underlying pathophysiological processes specific to rpAD, we explore potential changes in tau pathology and mitochondrial dysfunction in rpAD compared to tAD.
Methods:
We performed immunohistochemical and immunoblot analyses of tau, phosphorylated tau, and key regulators of mitochondrial dynamics and bioenergetics in postmortem human temporal cortex tissues obtained from patients diagnosed with tAD or rpAD, and tissues from age-matched normal subjects.
Results:
tAD was characterized by significant tau phosphorylation at the PHF1 epitope. Unexpectedly, rpAD showed milder PHF1 tau phosphorylation, similar to that of age-matched controls. Despite these differences in tau pathology, both tAD and rpAD exhibited a significant decrease in the key regulators of mitochondrial dynamics and bioenergetics compared to controls. However, the decline in mitochondrial dynamics regulators was more pronounced in rpAD.
Conclusions:
These findings suggest divergent pathological processes between tAD and rpAD, specifically in terms of tau pathology and mitochondrial dynamic abnormalities, which underscore the necessity for different approaches to understand and potentially treat various AD subtypes.
Insights
Rapidly progressive Alzheimer's disease (rpAD) shows distinct tau pathology and more severe mitochondrial dysfunction compared to typical Alzheimer's disease (tAD). These differences highlight the need for subtype-specific therapeutic strategies.
Area of Science:
- Neuroscience
- Pathology
- Biochemistry
Background:
- Rapidly progressive Alzheimer's disease (rpAD) is a subtype of Alzheimer's disease (AD) with accelerated cognitive decline.
- Both rpAD and typical AD (tAD) feature amyloid plaques and neurofibrillary tangles, but their composition may differ.
- Mitochondrial dysfunction is implicated in tAD, yet its role in rpAD remains unexplored.
Purpose of the Study:
- To investigate tau pathology and mitochondrial dysfunction in rpAD compared to tAD.
- To identify potential pathophysiological differences between AD subtypes.
Main Methods:
- Immunohistochemical and immunoblot analyses were conducted on postmortem human temporal cortex tissues.
- Tissues were obtained from patients with tAD, rpAD, and age-matched normal controls.
- Key regulators of tau phosphorylation and mitochondrial dynamics/bioenergetics were assessed.
Main Results:
- Typical AD (tAD) showed significant tau phosphorylation (PHF1 epitope), while rpAD exhibited milder phosphorylation, similar to controls.
- Both tAD and rpAD displayed reduced regulators of mitochondrial dynamics and bioenergetics compared to controls.
- The reduction in mitochondrial dynamics regulators was more pronounced in rpAD than in tAD.
Conclusions:
- Tau pathology differs between rpAD and tAD, with rpAD showing less phosphorylation.
- Mitochondrial dynamics are impaired in both rpAD and tAD, with a greater deficit in rpAD.
- These findings suggest distinct pathological pathways for AD subtypes, necessitating tailored treatment approaches.
More Related Videos
06:07Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment